INTERNATIONAL JOURNAL OF CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-08-23 ms2000002114558983

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;微生物
经验分享：3.24咨询是否接收散稿；
3.28回复感兴趣，欢迎投稿；
3.31投稿；
4.4under review;
4.27major revisions；
6.20修回；
6.21外审；
7.13major revisions；
8.11修回后决定；
8.15接收。
过程很艰辛，审稿人很专业，要求比较高。

74 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-11-12 capoex

投稿命中率:25.0
偏重的研究方向：实体肿瘤
经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中

67 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2019-12-14 0722

那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？

119 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-02-13 ZZLLZZ

偏重的研究方向：肿瘤;Environmental Research
经验分享：最近审的特别慢，一审拒稿特别慢，吐了

53 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2020-05-18 1486c94em67暂无昵称

审稿速度:2.0 | 投稿命中率:50.0
经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验

155 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-08-27 ms5000001852951271

偏重的研究方向：肿瘤;biomarker
经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-07-04 ay

6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-04-05 llmmzz0000

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;临床
经验分享：2021年12月13日提交；
2022年2月11日大修；
3月14日修回；
3月29日接收。

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2021-12-14 ms9482609815413700

想问下各位大佬，为什么我收不到密码重置的邮件呢？

66 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]

2022-03-04 1221c8e5m44(暂无昵称)

审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3
偏重的研究方向：Meta;epidemiology;Cancer
经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。

58 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务